Imipenem versus piperacillin/tazobactam for empiric treatment of febrile neutropenia in adults.

Link to article at PubMed

Related Articles

Imipenem versus piperacillin/tazobactam for empiric treatment of febrile neutropenia in adults.

Intern Med J. 2013 Jun 26;

Authors: Roohullah A, Moniwa A, Wood C, Humble M, Balm M, Carter J, Weinkove R

Abstract
Australian guidelines for febrile neutropenia recommend piperacillin/tazobactam (PIP-TAZ) or cefepime for first-line empiric treatment of febrile neutropenia. We compared outcomes among haematology patients before and after changing our first-line febrile neutropenia treatment from imipenem to PIP-TAZ. Forty-five patients received imipenem and 60 PIP-TAZ. Despite a higher rate of antibiotic modification in the PIP-TAZ cohort, treatment success and time to defervescence were similar, with a trend towards fewer Clostridium difficile infections in the PIP-TAZ cohort.

PMID: 23800137 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *